Frontiers in Cardiovascular Medicine (Jun 2024)

Potential perioperative cardiovascular outcomes in cannabis/cannabinoid users. A call for caution

  • Marco Echeverria-Villalobos,
  • Yosira Guevara,
  • Justin Mitchell,
  • David Ryskamp,
  • Joshua Conner,
  • Margo Bush,
  • Luis Periel,
  • Alberto Uribe,
  • Tristan E. Weaver

DOI
https://doi.org/10.3389/fcvm.2024.1343549
Journal volume & issue
Vol. 11

Abstract

Read online

BackgroundCannabis is one of the most widely used psychoactive substances. Its components act through several pathways, producing a myriad of side effects, of which cardiovascular events are the most life-threatening. However, only a limited number of studies address cannabis's perioperative impact on patients during noncardiac surgery.MethodsStudies were identified by searching the PubMed, Medline, EMBASE, and Google Scholar databases using relevant keyword combinations pertinent to the topic.ResultsCurrent evidence shows that cannabis use may cause several cardiovascular events, including abnormalities in cardiac rhythm, myocardial infarction, heart failure, and cerebrovascular events. Additionally, cannabis interacts with anticoagulants and antiplatelet agents, decreasing their efficacy. Finally, the interplay of cannabis with inhalational and intravenous anesthetic agents may lead to adverse perioperative cardiovascular outcomes.ConclusionsThe use of cannabis can trigger cardiovascular events that may depend on factors such as the duration of consumption, the route of administration of the drug, and the dose consumed, which places these patients at risk of drug-drug interactions with anesthetic agents. However, large prospective randomized clinical trials are needed to further elucidate gaps in the body of knowledge regarding which patient population has a greater risk of perioperative complications after cannabis consumption.

Keywords